In both melanoma and T cell acute lymphoblastic leukemia (T-ALL), a small-molecule IRAK1/4 inhibitor suppressed cell proliferation and enhanced chemotherapeutic responses [48, 49]. Here, IRAK1 is linked to acute lymphoblastic leukemia.